CRISPR says CTX310 cut triglycerides 63 percent at day 30 in 10 patients

CRISPR Therapeutics said a single intravenous dose of investigational CTX310 cut mean circulating ANGPTL3 by 65 percent and mean triglycerides by 63 percent at day 30 in 10 people with severe hypertriglyceridemia. The open-label Phase 1b cohort had a median baseline triglyceride level above 1,000 mg/dL. The company said there were no treatment-related serious adverse events and no clinically relevant liver-enzyme elevations as of the cutoff, with seven participants followed at least 90 days. CTX310 is not an approved treatment.